Cancer Policy FDA-mandated report finds “insufficient data” to determine safety of PFAS in cosmetics January 09, 2026Vol.52 No.1By Claire Marie Porter
Drugs & Targets FDA grants Enhertu Breakthrough Therapy designation as post-neoadjuvant therapy for HER2+ early breast cancer January 09, 2026Vol.52 No.1
Cancer Policy Angelo de Claro named acting director of FDA Oncology Center of Excellence December 19, 2025Vol.51 No.46By Jacquelyn Cobb
Drugs & Targets FDA grants regular approval to rucaparib for metastatic castration-resistant prostate cancer December 19, 2025Vol.51 No.46
Drugs & Targets FDA and OS Therapies hold Type C meeting regarding phase IIb clinical trial of OST-HER2 in the prevention or delay of recurrent, fully resected, pulmonary metastatic osteosarcoma December 19, 2025Vol.51 No.46
Drugs & Targets FDA awards National Priority Voucher to Tecvayli+Darzalex based on phase III study results December 19, 2025Vol.51 No.46
Podcast Testing for asbestos in talc-based cosmetics seems like a no-brainer—why did FDA withdraw a rule to standardize it? December 17, 2025
Regulatory News FDA withdraws proposed rule for asbestos testing in talc-based cosmeticsIt’s anyone’s guess whether the agency is preparing to strengthen or relax talc regulation December 12, 2025Vol.51 No.45By Claire Marie Porter
